Details of the Drug

General Information of Drug (ID: DMU8V4S)

Drug Name

Moxifloxacin

Synonyms

Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

401.4

Topological Polar Surface Area (xlogp)

0.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Bioavailability: The bioavailability of drug is 90% [3]
Clearance: The clearance of drug is 12 +/- 2 L/h [4]
Elimination: 22% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 11.5 - 15.6 hours [5]
Metabolism: The drug is metabolized via the glucuronide and sulphate conjugation [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.2344 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.6% [5]
Vd: The volume of distribution (Vd) of drug is 1.7-2.7 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 27.5 mg/mL [2]

Chemical Identifiers

Formula: C21H24FN3O4
IUPAC Name: 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
Canonical SMILES: COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
InChI: InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
InChIKey: FABPRXSRWADJSP-MEDUHNTESA-N

Cross-matching ID

PubChem CID: 152946
ChEBI ID: CHEBI:63611
CAS Number: 151096-09-2
DrugBank ID: DB00218
TTD ID: D0ZV0Z
VARIDT ID: DR00800
ACDINA ID: D00448

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU; GYRB_STAAU	Modulator	[7]
Staphylococcus Topoisomerase IV (Stap-coc parC)	TTIXTO3	PARC_STAAS	Modulator	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Moxifloxacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[14]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Moxifloxacin and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Telithromycin.	Bacterial infection [1A00-1C4Z]	[14]
-----------

Coadministration of a Drug Treating the Disease Different from Moxifloxacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[16]
Tretinoin	DM49DUI	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Tretinoin.	Acne vulgaris [ED80]	[17]
Sucralfate	DMP9HBO	Moderate	Decreased absorption of Moxifloxacin due to formation of complexes caused by Sucralfate.	Acne vulgaris [ED80]	[18]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Thioguanine.	Acute myeloid leukaemia [2A60]	[19]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[14]
Uracil mustard	DMHL7OB	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Uracil mustard.	Acute myeloid leukaemia [2A60]	[17]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Midostaurin.	Acute myeloid leukaemia [2A60]	[14]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Idarubicin.	Acute myeloid leukaemia [2A60]	[14]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Daunorubicin.	Acute myeloid leukaemia [2A60]	[14]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Arn-509.	Acute myeloid leukaemia [2A60]	[14]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[14]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Oliceridine.	Acute pain [MG31]	[14]
Magnesium Sulfate	DMVEK07	Moderate	Decreased absorption of Moxifloxacin due to formation of complexes caused by Magnesium Sulfate.	Acute pain [MG31]	[18]
Terfenadine	DM4KLPT	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Tacrine.	Alzheimer disease [8A20]	[15]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Galantamine.	Alzheimer disease [8A20]	[15]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Rivastigmine.	Alzheimer disease [8A20]	[15]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Donepezil.	Alzheimer disease [8A20]	[15]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Moxifloxacin and Metronidazole.	Amoebiasis [1A36]	[16]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Ivabradine.	Angina pectoris [BA40]	[20]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Bepridil.	Angina pectoris [BA40]	[14]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Dronedarone.	Angina pectoris [BA40]	[15]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[14]
Hydroxyzine	DMF8Y74	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[14]
Promazine	DMZAL7W	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Promazine.	Appearance/behaviour symptom [MB23]	[14]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Cilostazol.	Arterial occlusive disease [BD40]	[14]
Voriconazole	DMAOL2S	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Voriconazole.	Aspergillosis [1F20]	[14]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Posaconazole.	Aspergillosis [1F20]	[14]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Terbutaline.	Asthma [CA23]	[21]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Pirbuterol.	Asthma [CA23]	[21]
Isoetharine	DMITSEH	Moderate	Increased risk of prolong QT interval by the combination of Moxifloxacin and Isoetharine.	Asthma [CA23]	[21]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Moxifloxacin and Salbutamol.	Asthma [CA23]	[22]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Formoterol.	Asthma [CA23]	[21]
Atomoxetine	DM5L6HI	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[14]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[14]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[14]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Retigabine.	Behcet disease [4A62]	[14]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[23]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Moxifloxacin and Loperamide.	Bowel habit change [ME05]	[24]
Temozolomide	DMKECZD	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Temozolomide.	Brain cancer [2A00]	[17]
Lomustine	DMMWSUL	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Lomustine.	Brain cancer [2A00]	[17]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Eribulin.	Breast cancer [2C60-2C6Y]	[14]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Lapatinib.	Breast cancer [2C60-2C6Y]	[14]
Mitomycin	DMH0ZJE	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mitomycin.	Breast cancer [2C60-2C6Y]	[17]
Thiotepa	DMIZKOP	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Thiotepa.	Breast cancer [2C60-2C6Y]	[17]
Tamoxifen	DMLB0EZ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Tamoxifen.	Breast cancer [2C60-2C6Y]	[14]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Toremifene.	Breast cancer [2C60-2C6Y]	[15]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Bosutinib.	Breast cancer [2C60-2C6Y]	[14]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Sotalol.	Cardiac arrhythmia [BC9Z]	[14]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[14]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Moxifloxacin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Phenylbutazone	DMAYL0T	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Phenylbutazone.	Chronic pain [MG30]	[26]
Ketoprofen	DMRKXPT	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Ketoprofen.	Chronic pain [MG30]	[26]
Irinotecan	DMP6SC2	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Irinotecan.	Colorectal cancer [2B91]	[17]
Oxaliplatin	DMQNWRD	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Oxaliplatin.	Colorectal cancer [2B91]	[14]
Capecitabine	DMTS85L	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Capecitabine.	Colorectal cancer [2B91]	[17]
Isoproterenol	DMK7MEY	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Isoproterenol.	Conduction disorder [BC63]	[21]
Mestranol	DMG3F94	Moderate	Decreased absorption of Moxifloxacin due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[27]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Halothane.	Corneal disease [9A76-9A78]	[14]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Moxifloxacin and Propofol.	Corneal disease [9A76-9A78]	[28]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Sevoflurane.	Corneal disease [9A76-9A78]	[14]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Probucol.	Coronary atherosclerosis [BA80]	[14]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Methadone.	Cough [MD12]	[15]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Clofazimine.	Crohn disease [DD70]	[14]
Mycophenolic acid	DMU65NK	Moderate	Altered absorption of Moxifloxacin due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[29]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Mifepristone.	Cushing syndrome [5A70]	[15]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Pasireotide.	Cushing syndrome [5A70]	[14]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Osilodrostat.	Cushing syndrome [5A70]	[14]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Trimipramine.	Depression [6A70-6A7Z]	[14]
Imipramine	DM2NUH3	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Imipramine.	Depression [6A70-6A7Z]	[14]
Fluoxetine	DM3PD2C	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Fluoxetine.	Depression [6A70-6A7Z]	[14]
Nortriptyline	DM4KDYJ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Nortriptyline.	Depression [6A70-6A7Z]	[14]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Escitalopram.	Depression [6A70-6A7Z]	[15]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Clomipramine.	Depression [6A70-6A7Z]	[14]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Trazodone.	Depression [6A70-6A7Z]	[14]
Amitriptyline	DMK7F9S	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Amitriptyline.	Depression [6A70-6A7Z]	[14]
Amoxapine	DMKITQE	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Amoxapine.	Depression [6A70-6A7Z]	[14]
Mirtazapine	DML53ZJ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Mirtazapine.	Depression [6A70-6A7Z]	[14]
Protriptyline	DMNHTZI	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Protriptyline.	Depression [6A70-6A7Z]	[14]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Doxepin.	Depression [6A70-6A7Z]	[14]
Venlafaxine	DMR6QH0	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Venlafaxine.	Depression [6A70-6A7Z]	[14]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[14]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Deutetrabenazine.	Dystonic disorder [8A02]	[14]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Cannabidiol.	Epileptic encephalopathy [8A62]	[20]
Mefenamic acid	DMK7HFI	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Mefenamic acid.	Female pelvic pain [GA34]	[26]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Solifenacin.	Functional bladder disorder [GC50]	[14]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Pentamidine.	Fungal infection [1F29-1F2F]	[14]
Ketoconazole	DMPZI3Q	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Ketoconazole.	Fungal infection [1F29-1F2F]	[14]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[14]
Procarbazine	DMIK367	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[17]
Bleomycin	DMNER5S	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Bleomycin.	Hodgkin lymphoma [2B30]	[17]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Didanosine	DMI2QPE	Moderate	Decreased absorption of Moxifloxacin due to formation of complexes caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[32]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[33]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[15]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Moxifloxacin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[34]
Quinapril	DMR8H31	Moderate	Decreased absorption of Moxifloxacin due to formation of complexes caused by Quinapril.	Hypertension [BA00-BA04]	[20]
Fludrocortisone	DMUDIR8	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[35]
Meclofenamic acid	DM05FXR	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[36]
Melatonin	DMKWFBT	Minor	Decreased metabolism of Moxifloxacin caused by Melatonin mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[16]
Iron	DMAP8MV	Moderate	Decreased absorption of Moxifloxacin due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[37]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[15]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[15]
DTI-015	DMXZRW0	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by DTI-015.	Liver cancer [2C12]	[17]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Crizotinib.	Lung cancer [2C25]	[38]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Porfimer Sodium.	Lung cancer [2C25]	[39]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Ceritinib.	Lung cancer [2C25]	[15]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[17]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Osimertinib.	Lung cancer [2C25]	[14]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Selpercatinib.	Lung cancer [2C25]	[14]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Lumefantrine.	Malaria [1F40-1F45]	[16]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Halofantrine.	Malaria [1F40-1F45]	[40]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Hydroxychloroquine.	Malaria [1F40-1F45]	[14]
Quinine	DMSWYF5	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Quinine.	Malaria [1F40-1F45]	[14]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Primaquine.	Malaria [1F40-1F45]	[14]
Mefloquine	DMWT905	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Mefloquine.	Malaria [1F40-1F45]	[14]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[14]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[41]
Fludarabine	DMVRLT7	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Fludarabine.	Malignant haematopoietic neoplasm [2B33]	[17]
Pentostatin	DM0HXDS	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Pentostatin.	Mature B-cell leukaemia [2A82]	[17]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Idelalisib.	Mature B-cell leukaemia [2A82]	[42]
Chlorambucil	DMRKE63	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Chlorambucil.	Mature B-cell leukaemia [2A82]	[17]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[43]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Clofarabine.	Mature B-cell lymphoma [2A85]	[44]
Vincristine	DMINOX3	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vincristine.	Mature B-cell lymphoma [2A85]	[17]
Teniposide	DMLW57T	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Teniposide.	Mature B-cell lymphoma [2A85]	[17]
Mercaptopurine	DMTM2IK	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mercaptopurine.	Mature B-cell lymphoma [2A85]	[17]
Cytarabine	DMZD5QR	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cytarabine.	Mature B-cell lymphoma [2A85]	[17]
Mechlorethamine	DM0CVXA	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mechlorethamine.	Mature T-cell lymphoma [2A90]	[17]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Vemurafenib.	Melanoma [2C30]	[15]
Dacarbazine	DMNPZL4	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Dacarbazine.	Melanoma [2C30]	[17]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and LGX818.	Melanoma [2C30]	[14]
Ethinyl estradiol	DMODJ40	Moderate	Decreased absorption of Moxifloxacin due to formation of complexes caused by Ethinyl estradiol.	Menopausal disorder [GA30]	[27]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Moxifloxacin due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[15]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Moxifloxacin and Thalidomide.	Multiple myeloma [2A83]	[16]
Melphalan	DMOLNHF	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Melphalan.	Multiple myeloma [2A83]	[17]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Siponimod.	Multiple sclerosis [8A40]	[16]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Fingolimod.	Multiple sclerosis [8A40]	[15]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Ozanimod.	Multiple sclerosis [8A40]	[14]
Deflazacort	DMV0RNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Deflazacort.	Muscular dystrophy [8C70]	[35]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Methoxsalen.	Mycosis fungoides [2B01]	[16]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Romidepsin.	Mycosis fungoides [2B01]	[14]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[14]
Hydroxyurea	DMOQVU9	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Hydroxyurea.	Myeloproliferative neoplasm [2A20]	[17]
Busulfan	DMXYJ9C	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Busulfan.	Myeloproliferative neoplasm [2A20]	[17]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Droperidol.	Nausea/vomiting [MD90]	[15]
Prochlorperazine	DM53SRA	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Prochlorperazine.	Nausea/vomiting [MD90]	[14]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Promethazine.	Nausea/vomiting [MD90]	[14]
Palonosetron	DMBHMOX	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Palonosetron.	Nausea/vomiting [MD90]	[14]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Granisetron.	Nausea/vomiting [MD90]	[14]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Dolasetron.	Nausea/vomiting [MD90]	[14]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Ondansetron.	Nausea/vomiting [MD90]	[14]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Moxifloxacin and Bupropion.	Nicotine use disorder [6C4A]	[45]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Entrectinib.	Non-small cell lung cancer [2C25]	[14]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[20]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Lofexidine.	Opioid use disorder [6C43]	[14]
Rofecoxib	DM3P5DA	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Rofecoxib.	Osteoarthritis [FA00-FA05]	[26]
Valdecoxib	DMAY7H4	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Valdecoxib.	Osteoarthritis [FA00-FA05]	[26]
Diclofenac	DMPIHLS	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Diclofenac.	Osteoarthritis [FA00-FA05]	[26]
Naproxen	DMZ5RGV	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Naproxen.	Osteoarthritis [FA00-FA05]	[26]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Rucaparib.	Ovarian cancer [2C73]	[14]
Altretamine	DMKLAYG	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Altretamine.	Ovarian cancer [2C73]	[17]
Topotecan	DMP6G8T	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Topotecan.	Ovarian cancer [2C73]	[17]
Dextropropoxyphene	DM23HCX	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Dextropropoxyphene.	Pain [MG30-MG3Z]	[14]
Aspirin	DM672AH	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Aspirin.	Pain [MG30-MG3Z]	[36]
Etodolac	DM6WJO9	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Etodolac.	Pain [MG30-MG3Z]	[26]
Diflunisal	DM7EN8I	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Diflunisal.	Pain [MG30-MG3Z]	[26]
Ibuprofen	DM8VCBE	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Ibuprofen.	Pain [MG30-MG3Z]	[26]
Nabumetone	DMAT2XH	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Nabumetone.	Pain [MG30-MG3Z]	[26]
Buprenorphine	DMPRI8G	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Buprenorphine.	Pain [MG30-MG3Z]	[14]
Piroxicam	DMTK234	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Piroxicam.	Pain [MG30-MG3Z]	[26]
Streptozocin	DMOF7AT	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Streptozocin.	Pancreatic cancer [2C10]	[17]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Triclabendazole.	Parasitic worm infestation [1F90]	[14]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Pimavanserin.	Parkinsonism [8A00]	[14]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Moxifloxacin and Lindane.	Pediculosis [1G00]	[46]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Moxifloxacin and Famotidine.	Peptic ulcer [DA61]	[16]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[47]
Prednisone	DM2HG4X	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Prednisone.	Postoperative inflammation [1A00-CA43]	[35]
Choline salicylate	DM8P137	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[26]
Betamethasone	DMAHJEF	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Betamethasone.	Postoperative inflammation [1A00-CA43]	[35]
Hydrocortisone	DMGEMB7	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[35]
Ketorolac	DMI4EL5	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Ketorolac.	Postoperative inflammation [1A00-CA43]	[26]
Bromfenac	DMKB79O	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Bromfenac.	Postoperative inflammation [1A00-CA43]	[26]
Ritodrine	DM4V6RL	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Ritodrine.	Preterm labour/delivery [JB00]	[21]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Degarelix.	Prostate cancer [2C82]	[14]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Nilutamide.	Prostate cancer [2C82]	[14]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Relugolix.	Prostate cancer [2C82]	[14]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Bicalutamide.	Prostate cancer [2C82]	[14]
Alfuzosin	DMZVMKF	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Alfuzosin.	Prostate hyperplasia [GA90]	[14]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Verteporfin.	Psoriasis [EA90]	[20]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[14]
Fluphenazine	DMIT8LX	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Fluphenazine.	Psychotic disorder [6A20-6A25]	[14]
Triflupromazine	DMKFQJP	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Triflupromazine.	Psychotic disorder [6A20-6A25]	[14]
Sorafenib	DMS8IFC	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Sorafenib.	Renal cell carcinoma [2C90]	[14]
Salsalate	DM13P4C	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Salsalate.	Rheumatoid arthritis [FA20]	[26]
Meloxicam	DM2AR7L	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Meloxicam.	Rheumatoid arthritis [FA20]	[26]
Sulindac	DM2QHZU	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Sulindac.	Rheumatoid arthritis [FA20]	[26]
Celecoxib	DM6LOQU	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Celecoxib.	Rheumatoid arthritis [FA20]	[26]
Oxaprozin	DM9UB0P	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Oxaprozin.	Rheumatoid arthritis [FA20]	[26]
Flurbiprofen	DMGN4BY	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Flurbiprofen.	Rheumatoid arthritis [FA20]	[26]
Fenoprofen	DML5VQ0	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Fenoprofen.	Rheumatoid arthritis [FA20]	[26]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[35]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Leflunomide.	Rheumatoid arthritis [FA20]	[15]
Indomethacin	DMSC4A7	Moderate	Additive CNS depression effects by the combination of Moxifloxacin and Indomethacin.	Rheumatoid arthritis [FA20]	[26]
Tolmetin	DMWUIJE	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Tolmetin.	Rheumatoid arthritis [FA20]	[26]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Mesoridazine.	Schizophrenia [6A20]	[15]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Thioridazine.	Schizophrenia [6A20]	[15]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Moxifloxacin and Aripiprazole.	Schizophrenia [6A20]	[16]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Iloperidone.	Schizophrenia [6A20]	[15]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Paliperidone.	Schizophrenia [6A20]	[14]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Haloperidol.	Schizophrenia [6A20]	[15]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Perphenazine.	Schizophrenia [6A20]	[14]
Chlorpromazine	DMBGZI3	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Chlorpromazine.	Schizophrenia [6A20]	[14]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Clozapine.	Schizophrenia [6A20]	[14]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Trifluoperazine.	Schizophrenia [6A20]	[14]
Ziprasidone	DMM58JY	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Ziprasidone.	Schizophrenia [6A20]	[15]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Risperidone.	Schizophrenia [6A20]	[14]
Olanzapine	DMPFN6Y	Moderate	Increased risk of prolong QT interval by the combination of Moxifloxacin and Olanzapine.	Schizophrenia [6A20]	[16]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Amisulpride.	Schizophrenia [6A20]	[14]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Asenapine.	Schizophrenia [6A20]	[14]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Pimozide.	Schizophrenia [6A20]	[20]
Salicyclic acid	DM2F8XZ	Moderate	Additive CNS stimulant effects by the combination of Moxifloxacin and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[36]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Vardenafil.	Sexual dysfunction [HA00-HA01]	[14]
Floxuridine	DM04LR2	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Floxuridine.	Solid tumour/cancer [2A00-2F9Z]	[17]
Dactinomycin	DM2YGNW	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Dactinomycin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Methylprednisolone	DM4BDON	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[35]
Cyclophosphamide	DM4O2Z7	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cyclophosphamide.	Solid tumour/cancer [2A00-2F9Z]	[17]
Vinblastine	DM5TVS3	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vinblastine.	Solid tumour/cancer [2A00-2F9Z]	[17]
Ifosfamide	DMCT3I8	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[17]
Docetaxel	DMDI269	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[17]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Mitoxantrone	DMM39BF	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[17]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[14]
Etoposide	DMNH3PG	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Etoposide.	Solid tumour/cancer [2A00-2F9Z]	[17]
Epirubicin	DMPDW6T	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Prednisolone	DMQ8FR2	Major	Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[35]
Cisplatin	DMRHGI9	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[48]
Gemcitabine	DMSE3I7	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Gemcitabine.	Solid tumour/cancer [2A00-2F9Z]	[17]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Fluorouracil	DMUM7HZ	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Fluorouracil.	Solid tumour/cancer [2A00-2F9Z]	[17]
Taxol	DMUOT9V	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[17]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Vinorelbine	DMVXFYE	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vinorelbine.	Solid tumour/cancer [2A00-2F9Z]	[17]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Pitolisant.	Somnolence [MG42]	[14]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[14]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Moxifloxacin and Naltrexone.	Substance abuse [6C40]	[49]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[15]
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[50]
Plicamycin	DM7C8YV	Minor	Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Plicamycin.	Testicular cancer [2C80]	[17]
Anagrelide	DMSQ8MD	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Anagrelide.	Thrombocytosis [3B63]	[14]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Lenvatinib.	Thyroid cancer [2D10]	[14]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Cabozantinib.	Thyroid cancer [2D10]	[14]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Papaverine.	Tonus and reflex abnormality [MB47]	[51]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Tizanidine.	Tonus and reflex abnormality [MB47]	[14]
Mycophenolate mofetil	DMPQAGE	Moderate	Altered absorption of Moxifloxacin due to GI flora changes caused by Mycophenolate mofetil.	Transplant rejection [NE84]	[29]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Tacrolimus.	Transplant rejection [NE84]	[14]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[14]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[14]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[14]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Procainamide.	Ventricular tachyarrhythmia [BC71]	[14]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[14]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Moxifloxacin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[14]
-----------


⏷ Show the Full List of 272 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium stearyl fumarate	E00545	23665634	lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Moxifloxacin 400 mg tablet	400 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
2	BDDCS applied to over 900 drugs
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
9	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
10	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
11	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
12	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
13	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
14	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
15	Canadian Pharmacists Association.
16	Cerner Multum, Inc. "Australian Product Information.".
17	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
18	Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
19	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
22	Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
23	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
24	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
25	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
26	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
27	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
28	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
29	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
30	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
31	Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
32	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
33	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
34	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
35	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
36	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
37	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
38	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
40	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
41	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
42	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
43	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
44	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
45	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
46	Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
47	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
48	Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
50	Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
51	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]